DP

Diadema Partners Portfolio holdings

AUM $161M
This Quarter Est. Return
1 Year Est. Return
–
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$125M
AUM Growth
+$36.4M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
117
New
Increased
Reduced
Closed

Top Buys

1
+$18.9M
2
+$15.9M
3
+$9M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$6.88M
5
ARGX icon
argenx
ARGX
+$6.78M

Top Sells

1
+$9.05M
2
+$8.88M
3
+$6.68M
4
BPMC
Blueprint Medicines
BPMC
+$5.6M
5
AZN icon
AstraZeneca
AZN
+$3.93M

Sector Composition

1 Healthcare 100%
2 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS icon
51
Apellis Pharmaceuticals
APLS
$3.1B
– –
0
APVO icon
52
Aptevo Therapeutics
APVO
$21.8M
– –
-203
ARVN icon
53
Arvinas
ARVN
$699M
– –
0
JBIO
54
Jade Biosciences
JBIO
$431M
– –
0
AZN icon
55
AstraZeneca
AZN
$263B
– –
-30,000
BBIO icon
56
BridgeBio Pharma
BBIO
$10.5B
– –
0
BHVN icon
57
Biohaven
BHVN
$1.69B
– –
0
BMEA icon
58
Biomea Fusion
BMEA
$107M
– –
0
BMY icon
59
Bristol-Myers Squibb
BMY
$88.8B
– –
-160,000
BNTX icon
60
BioNTech
BNTX
$25.3B
– –
-8,767
BPMC
61
DELISTED
Blueprint Medicines
BPMC
– –
-64,193
CAPR icon
62
Capricor Therapeutics
CAPR
$286M
– –
0
CCCC icon
63
C4 Therapeutics
CCCC
$169M
– –
0
CLDX icon
64
Celldex Therapeutics
CLDX
$1.78B
– –
0
CMPX icon
65
Compass Therapeutics
CMPX
$731M
– –
0
CORT icon
66
Corcept Therapeutics
CORT
$8.29B
– –
0
CRDF icon
67
Cardiff Oncology
CRDF
$146M
– –
0
CRNX icon
68
Crinetics Pharmaceuticals
CRNX
$3.91B
– –
-25,900
CRSP icon
69
CRISPR Therapeutics
CRSP
$6.29B
– –
0
DNLI icon
70
Denali Therapeutics
DNLI
$2.44B
– –
-60,000
EOLS icon
71
Evolus
EOLS
$414M
– –
-97,423
ERAS icon
72
Erasca
ERAS
$686M
– –
-156,973
EWTX icon
73
Edgewise Therapeutics
EWTX
$1.59B
– –
-1,359
FOLD icon
74
Amicus Therapeutics
FOLD
$2.48B
– –
0
GERN icon
75
Geron
GERN
$766M
– –
-200,000
1 2
3
4 5